The 10 mg lock is the dose they put on the ECG study
Fifty-nine healthy men, 45-60 years, took vardenafil 10 mg and 80 mg in a crossover with placebo and moxifloxacin 400 mg. QT was read at one hour, near typical peak. Therapeutic 10 mg and the active control produced similar QTc shifts. The clinical meaning of small mean shifts is still described as unknown on the label.
That is why this desk titles 10 mg uses after the QT screen. The number is not a shy 2.5 mg first step invented for SERP rotation. 2.5 mg exists for selected patients. It is not the Yvessa lock.
Heart rate rose about 5 beats per minute after 10 mg versus placebo in that study. Do not call a mild pulse bump a failed screen.
Faint after 10 mg is a stop, not a reason to try 20
Syncope after a first 10 mg swallow can be hypotension, arrhythmia, or vasovagal overlay. It is not a cue to climb the ladder. Sit, document the time, and get evaluated if it recurs or if palpitations came with it.
Men with prior unexplained faints belong in the ECG conversation before any vardenafil, even if nobody has written 'long QT' in the notes yet.
Family sudden death under forty is a history item this markup wants named out loud. It is not a diagnosis. It is a reason to pause the 10 mg lock.
Who the label tells to avoid Levitra
Patients with congenital QT prolongation should avoid vardenafil. So should men on Class IA drugs (quinidine, procainamide) or Class III drugs (amiodarone, sotalol). A postmarketing study of vardenafil plus another QT-active drug showed an additive effect versus either alone.
That is a stop, not a 'monitor and hope' hedge. If the antiarrhythmic is real, pick another ED path with a clinician who has the ECG.
Ritonavir and other strong CYP3A4 inhibitors push vardenafil levels toward the exposures the 80 mg arm was meant to cover. Dose caps on the parent plan are not optional colour.
| Situation | Label posture | This markup |
|---|---|---|
| Congenital long QT | Avoid | Do not self-trial 10 mg |
| Amiodarone / sotalol / quinidine | Avoid | Different ED class conversation |
| Healthy ECG, no QT drugs | Usual 10 mg start possible | Still nitrate-screen |
| Ritonavir-level CYP3A4 block | Exposure can mimic high-dose PK | Use the labelled cap, not 20 mg bravado |
Drugs that are not Class IA or III but still matter
The hard avoid list is congenital long QT plus Class IA and III antiarrhythmics. Other QT-active drugs - some antipsychotics, some macrolides, some methadone stories - sit in the 'consider' language. That is a clinician stack review, not a home scoring system.
Hypokalaemia and extreme bradycardia make any QT-active combination uglier. A gastroenteritis week is a bad week to start 10 mg 'to see'.
Sildenafil and tadalafil are not QT-proof consolation prizes you start the same night you stop Levitra. They have their own nitrate and hypotension rules. The overlay compares clocks, not ECG certificates.
Admission med rec is where 10 mg quietly meets sotalol
Men who take Levitra as needed may not list it on a hospital admission. A new Class III drug then meets a weekend 10 mg at home. Teach them to name the PDE5 even if they last used it a month ago.
Inpatient teams should ask about ED tablets the same way they ask about GTN spray. This markup exists so the 10 mg lock is not treated as a lifestyle extra beneath the ECG.
Discharge summaries that start amiodarone need an explicit 'stop vardenafil' line if that was the home agent. A uses lock on a website does not appear in the discharge software. Someone has to type the stop.
Why the study used 80 mg if nobody should swallow that
Eighty milligrams is four times the labelled 20 mg ceiling. The thorough QT design used it because ritonavir-level CYP3A4 block can push vardenafil concentrations into that neighbourhood even when the tablet says 5 or 10 mg.
That is a PK cover, not a secret uses rung. Do not read the 80 mg arm as permission. Do read it as a reason to respect the labelled cap when a strong inhibitor is on the list.
Moxifloxacin 400 mg sat in the study as a positive control because regulators already know it moves QTc a little. Similarity to that control is a signal to think, not a claim that Levitra is an antibiotic.
The QT draft does not retire the class stops
Guanylate-cyclase stimulators such as riociguat sit with nitrates as absolute PDE5 stops. A clean QTc does not reopen those doors.
Poppers at a party are still nitrites. The 10 mg uses lock does not get a club exception.
If the cardiac list is messy, daily tadalafil 5 mg is not an automatic safer harbour. It has the same nitrate wall and a longer tail if a GTN spray is needed later. The long half-life is a problem when a nitrate might be required, not a comfort.
Why the lock is 10 mg, not a 2.5 mg floor
Neighbouring titles already used 2.5 or 5. This domain locked the mid start. Men who need 5 mg for AE or interactions still have that rung on the parent plan. 20 mg is the labelled ceiling, once daily.
Potency per milligram is higher than sildenafil. Ten milligrams is not a gentle cousin of sildenafil 10 mg. Do not convert 1:1.
Staxyn ODT has its own food and QT wording. Do not paste film-coated 10 mg counsel onto an orodispersible strip without reading that label.
QT draft next to the uses lock
- 10 mg usual start and Yvessa lock
- Avoid congenital long QT and Class IA/III antiarrhythmics
- Nitrates still absolute
- One PDE5 agent; one dose per day
What a 'QT screen' means in practice here
Yvessa is not asking readers to buy a consumer ECG ring and titrate vardenafil. The screen is a history: syncope, family sudden death, known long QT, and the antiarrhythmic list. An actual ECG is a clinician tool.
Sildenafil and tadalafil do not carry the same thorough-QT marketing weight in everyday counsel, which is why this note exists on vardenafil and not as a copied paragraph on every PDE5 page.
A normal ECG last year does not clear a new sotalol start this month. Re-open the list when the cardiac drugs change.
ODT vardenafil does not inherit this 10 mg film-coated lock
Staxyn and other orodispersible vardenafil products have their own food and QT sentences. Do not assume the Yvessa 10 mg film-coated uses lock transfers milligram-for-milligram onto a strip you dissolve on the tongue.
If the box in the drawer is ODT, read that leaflet. If it is film-coated 10 mg, this draft and the parent plan apply.
Switching formulations to 'dodge QT' is not a labelled strategy. The electrophysiology section is about vardenafil exposure, not about whether the tablet was chewed.
File the ECG history, then read the 10 mg plan
The parent Levitra 10 mg uses plan holds onset, food, and class fit. This draft only marks the QT wall so the lock does not look like a casual mid-start.
Syncope, arrhythmia symptoms, chest pain, or priapism past four hours: 144. A clean marketing slogan about a mid start does not replace the QT avoid list on the 10 mg uses lock. Name the antiarrhythmic list every time the bottle is renewed, not only on night one. A new Class III start reopens the screen even if last year's tracing was quiet.
Sources
- FDA / DailyMed LEVITRA - 10 mg usual start; 5-20 mg; thorough QT at 10 and 80 mg; Class IA/III and congenital long QT avoid.
- Levitra PI Table 1 - QTc vs moxifloxacin; heart-rate +5 bpm at 10 mg.
- Postmarketing additive QT study cited in section 5.7 / 12.2.
Checked against the current label and reviewed by Dr. Amélie Laurent. See Survey, Draft, Peer-check, Stamp.